

# Quinn T Ostrom

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8841876/publications.pdf>

Version: 2024-02-01

120  
papers

30,958  
citations

57631

44  
h-index

22102

113  
g-index

124  
all docs

124  
docs citations

124  
times ranked

28825  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exposure to radon and heavy particulate pollution and incidence of brain tumors. <i>Neuro-Oncology</i> , 2023, 25, 407-417.	0.6	5
2	Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. <i>Neuro-Oncology</i> , 2022, 24, 302-310.	0.6	29
3	The Epidemiology of Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 23-42.	0.9	15
4	Epidemiology of Pineoblastoma in the United States, 2000-2017. <i>Neuro-Oncology Practice</i> , 2022, 9, 149-157.	1.0	4
5	Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians. <i>Neuro-Oncology Practice</i> , 2022, 9, 165-182.	1.0	40
6	Aligning the Central Brain Tumor Registry of the United States (CBTRUS) histology groupings with current definitions. <i>Neuro-Oncology Practice</i> , 2022, 9, 317-327.	1.0	3
7	Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1989-2000.	0.6	27
8	Epidemiology of brainstem high-grade gliomas in children and adolescents in the United States, 2000-2017. <i>Neuro-Oncology</i> , 2021, 23, 990-998.	0.6	28
9	Epidemiology and Etiology of Glioblastoma. <i>Molecular Pathology Library</i> , 2021, , 3-19.	0.1	1
10	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab035.	0.4	3
11	Partitioned glioma heritability shows subtype-specific enrichment in immune cells. <i>Neuro-Oncology</i> , 2021, 23, 1304-1314.	0.6	12
12	The Shared Genetic Architectures Between Lung Cancer and Multiple Polygenic Phenotypes in Genome-Wide Association Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1156-1164.	1.1	13
13	Racial/ethnic disparities in treatment pattern and time to treatment for adults with glioblastoma in the US. <i>Journal of Neuro-Oncology</i> , 2021, 152, 603-615.	1.4	10
14	Role of Ethnicity and Geographic Location on Glioblastoma IDH1/IDH2 Mutations. <i>World Neurosurgery</i> , 2021, 149, e894-e912.	0.7	5
15	Brain and other central nervous system tumor statistics, 2021. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 381-406.	157.7	404
16	The shared genetic architecture between epidemiological and behavioral traits with lung cancer. <i>Scientific Reports</i> , 2021, 11, 17559.	1.6	10
17	Glioblastoma as an age-related neurological disorder in adults. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab125.	0.4	30
18	An updated histology recode for the analysis of primary malignant and nonmalignant brain and other central nervous system tumors in the Surveillance, Epidemiology, and End Results Program. <i>Neuro-Oncology Advances</i> , 2021, 3, vdaa175.	0.4	14

#	ARTICLE	IF	CITATIONS
19	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014–2018. <i>Neuro-Oncology</i> , 2021, 23, iii1-iii105.	0.6	804
20	Epidemiology of Brain and Other CNS Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 68.	2.0	43
21	Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. <i>International Journal of Cancer</i> , 2020, 146, 739-748.	2.3	23
22	Association between urbanicity and surgical treatment among patients with primary glioblastoma in the United States. <i>Neuro-Oncology Practice</i> , 2020, 7, 299-305.	1.0	3
23	Relative survival after diagnosis with a primary brain or other central nervous system tumor in the National Program of Cancer Registries, 2004 to 2014. <i>Neuro-Oncology Practice</i> , 2020, 7, 306-312.	1.0	18
24	Glioblastoma incidence rate trends in Canada and the United States compared with England, 1995–2015. <i>Neuro-Oncology</i> , 2020, 22, 301-302.	0.6	39
25	European genetic ancestry associated with risk of childhood ependymoma. <i>Neuro-Oncology</i> , 2020, 22, 1637-1646.	0.6	16
26	Proteins inform survival-based differences in patients with glioblastoma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa039.	0.4	3
27	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. <i>Neuro-Oncology</i> , 2020, 22, iv1-iv96.	0.6	1,175
28	Genetic predisposition to longer telomere length and risk of childhood, adolescent and adult-onset ependymoma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 173.	2.4	15
29	Sex-Specific Genetic Associations for Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Gastroenterology</i> , 2020, 159, 2065-2076.e1.	0.6	16
30	Sex Differences in Cancer Incidence and Survival: A Pan-Cancer Analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1389-1397.	1.1	82
31	Testing for causality between systematically identified risk factors and glioma: a Mendelian randomization study. <i>BMC Cancer</i> , 2020, 20, 508.	1.1	12
32	Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 495.	3.4	325
33	Association of metabolic syndrome with glioblastoma: a retrospective cohort study and review. <i>Neuro-Oncology Practice</i> , 2020, 7, 541-548.	1.0	5
34	The epidemiology of spinal schwannoma in the United States between 2006 and 2014. <i>Journal of Neurosurgery: Spine</i> , 2020, 32, 661-666.	0.9	21
35	Aspirin, NSAIDs, and Glioma Risk: Original Data from the Glioma International Case-Control Study and a Meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 555-562.	1.1	15
36	Sex-specific gene and pathway modeling of inherited glioma risk. <i>Neuro-Oncology</i> , 2019, 21, 71-82.	0.6	52

#	ARTICLE	IF	CITATIONS
37	Risk factors for childhood and adult primary brain tumors. <i>Neuro-Oncology</i> , 2019, 21, 1357-1375.	0.6	150
38	Whole Tumor Histogram Analysis Using DW MRI in Primary Central Nervous System Lymphoma Correlates with Tumor Biomarkers and Outcome. <i>Cancers</i> , 2019, 11, 1506.	1.7	11
39	Pilocytic astrocytoma: Where do they belong in cancer reporting?. <i>Neuro-Oncology</i> , 2019, 22, 298-300.	0.6	11
40	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. <i>Neuro-Oncology</i> , 2019, 21, v1-v100.	0.6	1,735
41	Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. <i>Neuro-Oncology Practice</i> , 2019, 6, 330-339.	1.0	17
42	Glioma incidence and survival variations by county-level socioeconomic measures. <i>Cancer</i> , 2019, 125, 3390-3400.	2.0	68
43	Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. <i>Journal of Neuro-Oncology</i> , 2019, 144, 53-63.	1.4	19
44	Sex is an important prognostic factor for glioblastoma but not for nonglioblastoma. <i>Neuro-Oncology Practice</i> , 2019, 6, 451-462.	1.0	36
45	Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 917-925.	1.1	23
46	Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. <i>Journal of Neuro-Oncology</i> , 2019, 143, 251-260.	1.4	52
47	Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. <i>Cancer Causes and Control</i> , 2019, 30, 477-488.	0.8	21
48	The epidemiology of central and extraventricular neurocytoma in the United States between 2006 and 2014. <i>Journal of Neuro-Oncology</i> , 2019, 143, 123-127.	1.4	27
49	Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. <i>PLoS ONE</i> , 2019, 14, e0219724.	1.1	25
50	Primary brain and other central nervous system tumors in Appalachia: regional differences in incidence, mortality, and survival. <i>Journal of Neuro-Oncology</i> , 2019, 142, 27-38.	1.4	16
51	Epidemiology and Molecular Epidemiology. <i>Neurosurgery Clinics of North America</i> , 2019, 30, 1-16.	0.8	30
52	Transcriptome-Wide Association Study Identifies New Candidate Susceptibility Genes for Glioma. <i>Cancer Research</i> , 2019, 79, 2065-2071.	0.4	26
53	Integrating germline and somatic genomic analysis to probe etiological mechanism in malignant glioma. <i>Oncotarget</i> , 2019, 10, 3086-3087.	0.8	0
54	Abstract 4173: Previously identified common glioma risk SNPs are associated with familial glioma. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
55	Abstract 2745: Tumor microenvironment and host genetics impact glioma progression in a Collaborative Cross-based orthotopic allograft model. , 2019, , .		0
56	Females have the survival advantage in glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 576-577.	0.6	122
57	The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. <i>Neuro-Oncology</i> , 2018, 20, 295-298.	0.6	46
58	Models of epigenetic age capture patterns of DNA methylation in glioma associated with molecular subtype, survival, and recurrence. <i>Neuro-Oncology</i> , 2018, 20, 942-953.	0.6	31
59	Brain metastases: epidemiology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 27-42.	1.0	198
60	Mendelian randomisation study of the relationship between vitamin D and risk of glioma. <i>Scientific Reports</i> , 2018, 8, 2339.	1.6	23
61	Epidemiology of Intracranial Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 30, 1-11.	1.3	78
62	Impact of atopy on risk of glioma: a Mendelian randomisation study. <i>BMC Medicine</i> , 2018, 16, 42.	2.3	38
63	Influence of obesity-related risk factors in the aetiology of glioma. <i>British Journal of Cancer</i> , 2018, 118, 1020-1027.	2.9	32
64	The elderly left behindâ€”changes in survival trends of primary central nervous system lymphoma over the past 4 decades. <i>Neuro-Oncology</i> , 2018, 20, 687-694.	0.6	159
65	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011â€”2015. <i>Neuro-Oncology</i> , 2018, 20, iv1-iv86.	0.6	1,624
66	Ageâ€”specific genomeâ€”wide association study in glioblastoma identifies increased proportion of â€”lower grade gliomaâ€”like features associated with younger age. <i>International Journal of Cancer</i> , 2018, 143, 2359-2366.	2.3	21
67	Survivorship in adults with malignant brain and other central nervous system tumor from 2000â€”2014. <i>Neuro-Oncology</i> , 2018, 20, vii6-vii16.	0.6	76
68	A comparison of relative survival and causeâ€”specific survival methods to measure net survival in cancer populations. <i>Cancer Medicine</i> , 2018, 7, 4773-4780.	1.3	20
69	Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. <i>Scientific Reports</i> , 2018, 8, 7352.	1.6	56
70	Epidemiology of Brain Tumors. <i>Neurologic Clinics</i> , 2018, 36, 395-419.	0.8	135
71	Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. <i>JAMA Oncology</i> , 2018, 4, 1254.	3.4	373
72	Complete prevalence of malignant primary brain tumors registry data in the United States compared with other common cancers, 2010. <i>Neuro-Oncology</i> , 2017, 19, now252.	0.6	48

#	ARTICLE	IF	CITATIONS
73	Integrated genomic analysis of survival outliers in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, now269.	0.6	23
74	Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. <i>Journal of Neuro-Oncology</i> , 2017, 133, 17-25.	1.4	17
75	Is mortality due to primary malignant brain and other central nervous system tumors decreasing?. <i>Journal of Neuro-Oncology</i> , 2017, 133, 265-275.	1.4	14
76	Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1503-1510.	0.6	18
77	Estimating the annual frequency of synchronous brain metastasis in the United States 2010–2013: a population-based study. <i>Journal of Neuro-Oncology</i> , 2017, 134, 55-64.	1.4	44
78	Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. <i>Neuro-Oncology</i> , 2017, 19, 1553-1564.	0.6	146
79	Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. <i>Nature Genetics</i> , 2017, 49, 789-794.	9.4	259
80	Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. <i>Journal of Neuro-Oncology</i> , 2017, 135, 433-441.	1.4	62
81	Do race and age vary in non-malignant central nervous system tumor incidences in the United States?. <i>Journal of Neuro-Oncology</i> , 2017, 134, 269-277.	1.4	8
82	CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. <i>Neuro-Oncology</i> , 2017, 19, v1-v88.	0.6	1,236
83	Brain tumor biobanking in the precision medicine era: building a high-quality resource for translational research in neuro-oncology. <i>Neuro-Oncology Practice</i> , 2017, 4, 220-228.	1.0	5
84	Comparative Brain and Central Nervous System Tumor Incidence and Survival between the United States and Taiwan Based on Population-Based Registry. <i>Frontiers in Public Health</i> , 2016, 4, 151.	1.3	40
85	Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995–2012. <i>Journal of Neuro-Oncology</i> , 2016, 128, 419-429.	1.4	14
86	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004–2012, varying). <i>Journal of Neuro-Oncology</i> , 2016, 130, 31-42.	1.4	35
87	CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009–2013. <i>Neuro-Oncology</i> , 2016, 18, v1-v75.	0.6	995
88	Epidemiology of Glioblastoma and Trends in Glioblastoma Survivorship. , 2016, , 11-19.		3
89	Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. <i>Neuro-Oncology</i> , 2016, 18, 70-77.	0.6	90
90	Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. <i>Cell</i> , 2016, 164, 550-563.	13.5	1,695

#	ARTICLE	IF	CITATIONS
91	Understanding inherited genetic risk of adult glioma – a review. <i>Neuro-Oncology Practice</i> , 2016, 3, 10-16.	1.0	62
92	American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. <i>Neuro-Oncology</i> , 2016, 18, i1-i50.	0.6	212
93	Abstract 129: Integrated genomic analysis of survival outliers in glioblastoma. , 2016, , .		0
94	Years of life lived with disease and years of potential life lost in children who die of cancer in the United States, 2009. <i>Cancer Medicine</i> , 2015, 4, 608-619.	1.3	36
95	Descriptive Epidemiology of Spinal Meningiomas in the United States. <i>Spine</i> , 2015, 40, E886-E889.	1.0	56
96	International Differences in Treatment and Clinical Outcomes for High Grade Glioma. <i>PLoS ONE</i> , 2015, 10, e0129602.	1.1	11
97	Epidemiology of Gliomas. <i>Cancer Treatment and Research</i> , 2015, 163, 1-14.	0.2	319
98	Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007–2011. <i>Neuro-Oncology</i> , 2015, 16, x1-x36.	0.6	414
99	Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004–2011. <i>Journal of Neuro-Oncology</i> , 2015, 123, 43-51.	1.4	24
100	Response to "The epidemiology of glioma in adults: a 'state of the science' review". <i>Neuro-Oncology</i> , 2015, 17, 624-626.	0.6	29
101	Incidence of vestibular schwannomas in the United States. <i>Journal of Neuro-Oncology</i> , 2015, 124, 223-228.	1.4	105
102	Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States. <i>Neuro-Oncology</i> , 2015, 17, 1166-1173.	0.6	169
103	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. <i>Neuro-Oncology</i> , 2015, 17, iv1-iv62.	0.6	1,727
104	Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. <i>Cancer</i> , 2015, 121, 102-112.	2.0	98
105	Genome-Wide Methylation Analyses in Glioblastoma Multiforme. <i>PLoS ONE</i> , 2014, 9, e89376.	1.1	45
106	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. <i>Neuro-Oncology</i> , 2014, 16, iv1-iv63.	0.6	1,253
107	Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. <i>Neuro-Oncology</i> , 2014, 16, 1333-1340.	0.6	11
108	The descriptive epidemiology of atypical teratoid/rhabdoid tumors in the United States, 2001-2010. <i>Neuro-Oncology</i> , 2014, 16, 1392-1399.	0.6	100

#	ARTICLE	IF	CITATIONS
109	The epidemiology of glioma in adults: a "state of the science" review. <i>Neuro-Oncology</i> , 2014, 16, 896-913.	0.6	1,586
110	Epidemiologic and Molecular Prognostic Review of Glioblastoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1985-1996.	1.1	933
111	Descriptive epidemiology of pituitary tumors in the United States, 2004-2009. <i>Journal of Neurosurgery</i> , 2014, 121, 527-535.	0.9	130
112	Childhood Brain Tumor Epidemiology: A Brain Tumor Epidemiology Consortium Review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2716-2736.	1.1	290
113	The Somatic Genomic Landscape of Glioblastoma. <i>Cell</i> , 2013, 155, 462-477.	13.5	3,979
114	Gene markers in brain tumors: What the epileptologist should know. <i>Epilepsia</i> , 2013, 54, 25-29.	2.6	18
115	CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010. <i>Neuro-Oncology</i> , 2013, 15, ii1-ii56.	0.6	5,799
116	Methylation markers of malignant potential in meningiomas. <i>Journal of Neurosurgery</i> , 2013, 119, 899-906.	0.9	25
117	Family History of Cancer in Benign Brain Tumor Subtypes Versus Gliomas. <i>Frontiers in Oncology</i> , 2012, 2, 19.	1.3	25
118	Current State of Our Knowledge on Brain Tumor Epidemiology. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 329-335.	2.0	86
119	Incidence patterns for primary malignant spinal cord gliomas: a Surveillance, Epidemiology, and End Results study. <i>Journal of Neurosurgery: Spine</i> , 2011, 14, 742-747.	0.9	41
120	Prevalence of autoimmunity and atopy in US adults with glioblastoma and meningioma. <i>Neuro-Oncology</i> , 0, , .	0.6	1